Flucloxacillin is not used in the United States because it has never been approved by the FDA. The drug was simply never submitted for or granted regulatory approval in the US market, even though it became a frontline antibiotic in the UK, Australia, and much of Europe. The reason comes down to a combination of factors: the US already had closely related alternatives on the market, and flucloxacillin carries a notable risk of liver injury that may have made pursuing FDA approval less appealing to manufacturers.
The US Already Had Equivalent Drugs
Flucloxacillin belongs to a family of antibiotics called isoxazolyl penicillins, which were specifically designed to resist the enzyme that common staph bacteria use to destroy standard penicillin. Several drugs in this same family were developed around the same time, including dicloxacillin, cloxacillin, and nafcillin. The US market adopted dicloxacillin and nafcillin as its go-to options for staph infections, while the UK and Australia settled on flucloxacillin.
These drugs work through the same mechanism and target the same bacteria. Clinical studies comparing dicloxacillin and flucloxacillin in staph infections, including chronic bone infections and post-surgical infections, found equivalent results. With effective alternatives already approved and widely prescribed in the US, there was no commercial incentive for a pharmaceutical company to invest in the lengthy and expensive FDA approval process for flucloxacillin. It would have been entering a market where the need was already met.
Flucloxacillin’s Liver Toxicity Risk
One factor that likely discouraged any push for US approval is flucloxacillin’s association with a specific type of liver injury called cholestatic hepatitis, where bile flow from the liver becomes blocked. Roughly 1 in 15,000 people who take flucloxacillin develop this reaction. That number sounds small, but for a widely prescribed antibiotic given to millions of patients, it translates to a meaningful number of cases each year.
A Swedish review of 77 liver reactions linked to this drug family found that flucloxacillin was the most commonly implicated, with an estimated incidence of 1 in 11,000 to 1 in 30,000 prescriptions. The liver damage tends to be cholestatic, meaning it primarily affects bile drainage rather than destroying liver cells directly, but it can follow a prolonged course. One documented case persisted for seven years. Women, older patients, and those on higher doses appeared to face greater risk. Australian and Swedish researchers flagged the pattern as a significant safety signal in the 1990s.
All the isoxazolyl penicillins can cause liver reactions, but the reporting rates for flucloxacillin have consistently been higher than for dicloxacillin or cloxacillin. This difference gave US regulators and drug manufacturers little reason to consider flucloxacillin a superior option worth pursuing.
Where Flucloxacillin Is Standard Treatment
Outside the US, flucloxacillin is one of the most commonly prescribed antibiotics. The UK’s National Health Service lists it as a treatment for skin infections, chest infections, ear infections, bone infections (osteomyelitis), and pneumonia. In Australia, it holds a similar position as first-line therapy for staph skin and soft tissue infections. It is taken orally, with a bioavailability of 50 to 70 percent, making it practical for outpatient treatment of infections that would otherwise require hospital-based intravenous antibiotics.
For patients in these countries, flucloxacillin is as routine as amoxicillin. Doctors prescribe it frequently for cellulitis, abscesses, infected wounds, and other bacterial skin infections caused by staphylococcus. Its absence from the US formulary is not a reflection of it being unsafe or ineffective in those settings. It simply reflects the fact that different countries approved different members of the same drug family decades ago, and those choices stuck.
What US Doctors Prescribe Instead
If you’re in the US and have a staph infection that would be treated with flucloxacillin elsewhere, your doctor will typically prescribe dicloxacillin for oral treatment or nafcillin for intravenous treatment. Cephalosporins like cephalexin are also commonly used. For methicillin-resistant staph (MRSA), none of these drugs work, and doctors turn to entirely different antibiotics regardless of country.
The clinical outcomes are comparable. Dicloxacillin and flucloxacillin have nearly identical mechanisms, similar oral absorption, and overlapping dosing schedules. A patient in London receiving flucloxacillin for a skin infection and a patient in New York receiving dicloxacillin are getting functionally the same treatment.
Traveling to the US With Flucloxacillin
If you’ve been prescribed flucloxacillin in another country and plan to travel to the United States, the rules are strict. US Customs and Border Protection states that only medications legally prescribable in the US may be imported for personal use. Because flucloxacillin is not FDA-approved, it could technically be confiscated at the border, even with a valid foreign prescription.
If you need to travel with flucloxacillin, keep it in its original labeled container and carry a letter from your prescribing doctor written in English that explains your condition and why you need the medication. Bring no more than a 90-day supply. In practice, small quantities for personal use during a short visit are less likely to be flagged, but there is no legal guarantee the medication will be allowed through. If you’re relocating to the US or planning an extended stay, you’ll need to see a US doctor who can prescribe an equivalent alternative like dicloxacillin.